30.61
price up icon1.19%   0.36
 
loading
전일 마감가:
$30.25
열려 있는:
$30.25
하루 거래량:
1.75M
Relative Volume:
1.04
시가총액:
$5.05B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
15.70
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
+4.29%
1개월 성능:
+6.40%
6개월 성능:
+5.48%
1년 성능:
+31.88%
1일 변동 폭
Value
$29.70
$30.92
1주일 범위
Value
$29.30
$30.92
52주 변동 폭
Value
$22.90
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
명칭
Alkermes Plc
Name
전화
00-353-1-772-8000
Name
주소
CONNAUGHT HOUSE, DUBLIN 4
Name
직원
1,800
Name
트위터
@alkermes
Name
다음 수익 날짜
2024-10-24
Name
최신 SEC 제출 서류
Name
ALKS's Discussions on Twitter

ALKS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
30.61 4.84B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.35 50.14B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
168.63 72.38B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.79 4.22M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.03 45.51B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.78 19.45B 16.54B -1.64B 749.00M -1.45

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-28 개시 Needham Buy
2025-03-13 개시 RBC Capital Mkts Sector Perform
2025-03-04 업그레이드 UBS Sell → Neutral
2025-02-11 개시 Deutsche Bank Buy
2024-11-05 업그레이드 Stifel Hold → Buy
2024-06-17 개시 TD Cowen Buy
2024-03-19 개시 Robert W. Baird Outperform
2024-02-20 다운그레이드 UBS Neutral → Sell
2023-11-20 재개 JP Morgan Neutral
2023-10-24 업그레이드 Evercore ISI In-line → Outperform
2023-10-17 개시 UBS Neutral
2022-11-03 업그레이드 Piper Sandler Neutral → Overweight
2022-10-14 업그레이드 BofA Securities Underperform → Neutral
2022-08-16 개시 Piper Sandler Neutral
2022-04-22 재개 Goldman Buy
2022-04-20 개시 Goldman Buy
2022-01-27 업그레이드 Cantor Fitzgerald Hold → Overweight
2021-12-01 개시 Citigroup Neutral
2021-10-07 업그레이드 Jefferies Hold → Buy
2021-09-02 다운그레이드 BofA Securities Neutral → Underperform
2020-10-15 업그레이드 Mizuho Neutral → Buy
2020-07-30 다운그레이드 Goldman Neutral → Sell
2020-02-14 다운그레이드 BofA/Merrill Buy → Neutral
2020-02-14 재확인 H.C. Wainwright Neutral
2020-02-14 다운그레이드 JP Morgan Overweight → Neutral
2020-02-06 개시 Mizuho Neutral
2020-01-31 업그레이드 Wolfe Research Underperform → Peer Perform
2019-09-05 업그레이드 Morgan Stanley Underweight → Equal-Weight
2019-07-15 업그레이드 Goldman Sell → Neutral
2019-05-31 개시 H.C. Wainwright Neutral
2019-05-01 다운그레이드 Citigroup Buy → Neutral
2018-12-19 다운그레이드 Goldman Neutral → Sell
2018-12-14 개시 Wolfe Research Underperform
2018-12-13 다운그레이드 Credit Suisse Outperform → Underperform
2018-11-05 개시 Piper Jaffray Neutral
2018-08-07 개시 Stifel Hold
2018-06-21 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2018-06-06 개시 B. Riley FBR, Inc. Buy
2018-05-16 업그레이드 Citigroup Neutral → Buy
2018-05-11 개시 BofA/Merrill Buy
모두보기

Alkermes Plc 주식(ALKS)의 최신 뉴스

pulisher
May 31, 2025

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation? - simplywall.st

May 31, 2025
pulisher
May 31, 2025

Where are the Opportunities in (ALKS) - news.stocktradersdaily.com

May 31, 2025
pulisher
May 29, 2025

Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 20 - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Alkermes (ALKS) to Present New Findings on ALKS 2680 at SLEEP 2025 | ALKS Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - PR Newswire

May 29, 2025
pulisher
May 28, 2025

Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga

May 28, 2025
pulisher
May 28, 2025

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

May 28, 2025
pulisher
May 28, 2025

Needham Initiates Alkermes Public at Buy With $45 Price Target - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Needham's Positive Outlook on Alkermes (ALKS) with Promising Sal - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Needham Initiates Coverage on Alkermes (ALKS) with Buy Rating | ALKS Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Needham's Positive Outlook on Alkermes (ALKS) with Promising Sales Projections | ALKS Stock News - GuruFocus

May 28, 2025
pulisher
May 23, 2025

Controlled Release Drug Delivery Market Generated - openPR.com

May 23, 2025
pulisher
May 21, 2025

Alkermes Shareholders Approve Amendments at Annual Meeting - TipRanks

May 21, 2025
pulisher
May 20, 2025

(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 20, 2025
pulisher
May 20, 2025

Alkermes price target raised to $35 from $34 at BofA - MSN

May 20, 2025
pulisher
May 16, 2025

Nanotechnology Drug Delivery Market Generated Opportunities, - openPR.com

May 16, 2025
pulisher
May 15, 2025

Stifel maintains Alkermes stock Buy rating, $42 target By Investing.com - Investing.com Nigeria

May 15, 2025
pulisher
May 13, 2025

Drug Addiction Treatment Market Projected To Witness Massive - openPR.com

May 13, 2025
pulisher
May 12, 2025

Drug Abuse Treatment Market Grows Amid Rising Substance Abuse - openPR.com

May 12, 2025
pulisher
May 12, 2025

Cantor Fitzgerald maintains $43 target on Alkermes stock By Investing.com - Investing.com Nigeria

May 12, 2025
pulisher
May 12, 2025

Controlled Release Drug Delivery Market is in trends - openPR.com

May 12, 2025
pulisher
May 12, 2025

Alkermes plc Earnings Call Highlights Growth and R&D Progress - MSN

May 12, 2025
pulisher
May 10, 2025

When the Price of (ALKS) Talks, People Listen - news.stocktradersdaily.com

May 10, 2025
pulisher
May 03, 2025

Alkermes plc (ALKS): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey

May 03, 2025
pulisher
May 03, 2025

Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025
pulisher
May 03, 2025

Alkermes has near-term catalyst with narcolepsy data, says H.C. Wainwright - TipRanks

May 03, 2025
pulisher
May 03, 2025

BlackRock, Inc. Reduces Stake in Alkermes PLC: A Detailed Analysis - GuruFocus

May 03, 2025
pulisher
May 02, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire

May 02, 2025
pulisher
May 02, 2025

RBC Capital Raises Price Target for Alkermes (ALKS) to $40 | ALKS Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alkermes' Q1 Earnings and Revenues Fall Short of Estimates - Nasdaq

May 02, 2025
pulisher
May 02, 2025

Alkermes (ALKS) Reaffirms 2025 Financial Outlook and Awaits Key Trial Results | ALKS Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | AL - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | ALKS Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Baird Increases Price Target for Alkermes (ALKS) on Promising Ou - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Baird Increases Price Target for Alkermes (ALKS) on Promising Outlook | ALKS Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

RBC Raises Price Target on Alkermes to $40 From $39, Keeps Sector Perform Rating - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo

May 02, 2025
pulisher
May 02, 2025

Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Pro - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alkermes: Q1 Earnings Snapshot - MySA

May 02, 2025
pulisher
May 02, 2025

Alkermes plc Reports Q1 2025 Financial Results - TipRanks

May 02, 2025
pulisher
May 01, 2025

Alkermes Plc earnings missed by $0.18, revenue fell short of estimates - Investing.com South Africa

May 01, 2025
pulisher
May 01, 2025

Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible (NASDAQ:ALKS) - Seeking Alpha

May 01, 2025
pulisher
May 01, 2025

Chondrosarcoma Market: Epidemiology, Therapies, Companies, - openPR.com

May 01, 2025
pulisher
May 01, 2025

Alkermes to Report First Quarter Financial Results on May 1, 2025 - PR Newswire UK

May 01, 2025
pulisher
May 01, 2025

Alkermes Q1 2025 Earnings Call Transcript - MarketBeat

May 01, 2025
pulisher
May 01, 2025

Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Alkermes Q1 Earnings, Revenue Decline - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Alkermes Plc reports results for the quarter ended March 31Earnings Summary - TradingView

May 01, 2025
pulisher
May 01, 2025

Alkermes PLC Q1 2025 Earnings: EPS of $0.13 Beats Estimate, Reve - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Alkermes (ALKS) Exceeds Q1 Revenue Expectations and Advances Ore - GuruFocus

May 01, 2025

Alkermes Plc (ALKS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_specialty_generic RGC
$877.00
price up icon 18.36%
drug_manufacturers_specialty_generic HCM
$13.89
price up icon 0.22%
$123.02
price down icon 0.52%
drug_manufacturers_specialty_generic RDY
$14.72
price down icon 0.20%
$318.85
price down icon 0.47%
$16.78
price down icon 4.28%
자본화:     |  볼륨(24시간):